Whether or not the edit is marked as minor (no longer in use) (minor_edit) | false |
Edit count of the user (user_editcount) | 1725 |
Name of the user account (user_name) | 'Chrisvanlang' |
Age of the user account (user_age) | 278415795 |
Groups (including implicit) the user is in (user_groups) | [
0 => 'extendedconfirmed',
1 => '*',
2 => 'user',
3 => 'autoconfirmed'
] |
Rights that the user has (user_rights) | [
0 => 'extendedconfirmed',
1 => 'createaccount',
2 => 'read',
3 => 'edit',
4 => 'createtalk',
5 => 'writeapi',
6 => 'editmyusercss',
7 => 'editmyuserjs',
8 => 'viewmywatchlist',
9 => 'editmywatchlist',
10 => 'viewmyprivateinfo',
11 => 'editmyprivateinfo',
12 => 'editmyoptions',
13 => 'abusefilter-view',
14 => 'abusefilter-log',
15 => 'abusefilter-log-detail',
16 => 'centralauth-merge',
17 => 'vipsscaler-test',
18 => 'ep-bereviewer',
19 => 'collectionsaveasuserpage',
20 => 'reupload-own',
21 => 'move-rootuserpages',
22 => 'move-categorypages',
23 => 'createpage',
24 => 'minoredit',
25 => 'purge',
26 => 'sendemail',
27 => 'applychangetags',
28 => 'ep-enroll',
29 => 'mwoauthmanagemygrants',
30 => 'reupload',
31 => 'upload',
32 => 'move',
33 => 'collectionsaveascommunitypage',
34 => 'autoconfirmed',
35 => 'editsemiprotected',
36 => 'movestable',
37 => 'autoreview',
38 => 'transcode-reset',
39 => 'skipcaptcha'
] |
Global groups that the user is in (global_user_groups) | [] |
Whether or not a user is editing through the mobile interface (user_mobile) | false |
Page ID (page_id) | 0 |
Page namespace (page_namespace) | 0 |
Page title without namespace (page_title) | 'Vasant Narasimhan' |
Full page title (page_prefixedtitle) | 'Vasant Narasimhan' |
Move protection level of the page (page_restrictions_move) | [] |
Last ten users to contribute to the page (page_recent_contributors) | '' |
Action (action) | 'edit' |
Edit summary/reason (summary) | '' |
Old content model (old_content_model) | '' |
New content model (new_content_model) | 'wikitext' |
Old page wikitext, before the edit (old_wikitext) | '' |
New page wikitext, after the edit (new_wikitext) | ''''Vasant Narasimhan''' is the Global Head of Drug Development and [[Chief Medical Officer]] for [[Novartis]]. Vasant received his bachelor's degree in biological sciences from [[University of Chicago]] and his [[M.D.]] from [[Harvard Medical School]] and his master's degree in [[public policy]] from the [[John F. Kennedy School of Government]].<ref name="Novartis Bio">{{cite web|title=Vasant (Vas) Narasimhan|url=https://www.novartis.com/sites/www.novartis.com/files/cv-vasant-narasimhan-en.pdf|publisher=Novartis|accessdate=5 September 2017}}</ref> On September 5, 2017, he was named the successor of [[Joseph Jimenez]] as [[CEO]] of [[Novartis]].<ref name="Bloomberg Announcement">{{cite news|title=Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor|url=https://www.bloomberg.com/news/articles/2017-09-04/novartis-names-narasimhan-ceo-after-jimenez-retires-next-year|accessdate=5 September 2017|work=Bloomberg.com|agency=Bloomberg Technology|date=4 September 2017}}</ref>
He is a member of the U.S. [[National Academy of Medicine]].' |
Unified diff of changes made by edit (edit_diff) | '@@ -1,1 +1,3 @@
+'''Vasant Narasimhan''' is the Global Head of Drug Development and [[Chief Medical Officer]] for [[Novartis]]. Vasant received his bachelor's degree in biological sciences from [[University of Chicago]] and his [[M.D.]] from [[Harvard Medical School]] and his master's degree in [[public policy]] from the [[John F. Kennedy School of Government]].<ref name="Novartis Bio">{{cite web|title=Vasant (Vas) Narasimhan|url=https://www.novartis.com/sites/www.novartis.com/files/cv-vasant-narasimhan-en.pdf|publisher=Novartis|accessdate=5 September 2017}}</ref> On September 5, 2017, he was named the successor of [[Joseph Jimenez]] as [[CEO]] of [[Novartis]].<ref name="Bloomberg Announcement">{{cite news|title=Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor|url=https://www.bloomberg.com/news/articles/2017-09-04/novartis-names-narasimhan-ceo-after-jimenez-retires-next-year|accessdate=5 September 2017|work=Bloomberg.com|agency=Bloomberg Technology|date=4 September 2017}}</ref>
+He is a member of the U.S. [[National Academy of Medicine]].
' |
New page size (new_size) | 1049 |
Old page size (old_size) | 0 |
Size change in edit (edit_delta) | 1049 |
Lines added in edit (added_lines) | [
0 => ''''Vasant Narasimhan''' is the Global Head of Drug Development and [[Chief Medical Officer]] for [[Novartis]]. Vasant received his bachelor's degree in biological sciences from [[University of Chicago]] and his [[M.D.]] from [[Harvard Medical School]] and his master's degree in [[public policy]] from the [[John F. Kennedy School of Government]].<ref name="Novartis Bio">{{cite web|title=Vasant (Vas) Narasimhan|url=https://www.novartis.com/sites/www.novartis.com/files/cv-vasant-narasimhan-en.pdf|publisher=Novartis|accessdate=5 September 2017}}</ref> On September 5, 2017, he was named the successor of [[Joseph Jimenez]] as [[CEO]] of [[Novartis]].<ref name="Bloomberg Announcement">{{cite news|title=Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor|url=https://www.bloomberg.com/news/articles/2017-09-04/novartis-names-narasimhan-ceo-after-jimenez-retires-next-year|accessdate=5 September 2017|work=Bloomberg.com|agency=Bloomberg Technology|date=4 September 2017}}</ref>',
1 => 'He is a member of the U.S. [[National Academy of Medicine]].'
] |
Lines removed in edit (removed_lines) | [] |
New page wikitext, pre-save transformed (new_pst) | ''''Vasant Narasimhan''' is the Global Head of Drug Development and [[Chief Medical Officer]] for [[Novartis]]. Vasant received his bachelor's degree in biological sciences from [[University of Chicago]] and his [[M.D.]] from [[Harvard Medical School]] and his master's degree in [[public policy]] from the [[John F. Kennedy School of Government]].<ref name="Novartis Bio">{{cite web|title=Vasant (Vas) Narasimhan|url=https://www.novartis.com/sites/www.novartis.com/files/cv-vasant-narasimhan-en.pdf|publisher=Novartis|accessdate=5 September 2017}}</ref> On September 5, 2017, he was named the successor of [[Joseph Jimenez]] as [[CEO]] of [[Novartis]].<ref name="Bloomberg Announcement">{{cite news|title=Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor|url=https://www.bloomberg.com/news/articles/2017-09-04/novartis-names-narasimhan-ceo-after-jimenez-retires-next-year|accessdate=5 September 2017|work=Bloomberg.com|agency=Bloomberg Technology|date=4 September 2017}}</ref>
He is a member of the U.S. [[National Academy of Medicine]].' |
Parsed HTML source of the new revision (new_html) | '<div class="mw-parser-output"><p><b>Vasant Narasimhan</b> is the Global Head of Drug Development and <a href="/https/en.m.wikipedia.org/wiki/Chief_Medical_Officer" title="Chief Medical Officer">Chief Medical Officer</a> for <a href="/https/en.m.wikipedia.org/wiki/Novartis" title="Novartis">Novartis</a>. Vasant received his bachelor's degree in biological sciences from <a href="/https/en.m.wikipedia.org/wiki/University_of_Chicago" title="University of Chicago">University of Chicago</a> and his <a href="/https/en.m.wikipedia.org/wiki/M.D." class="mw-redirect" title="M.D.">M.D.</a> from <a href="/https/en.m.wikipedia.org/wiki/Harvard_Medical_School" title="Harvard Medical School">Harvard Medical School</a> and his master's degree in <a href="/https/en.m.wikipedia.org/wiki/Public_policy" title="Public policy">public policy</a> from the <a href="/https/en.m.wikipedia.org/wiki/John_F._Kennedy_School_of_Government" title="John F. Kennedy School of Government">John F. Kennedy School of Government</a>.<sup id="cite_ref-Novartis_Bio_1-0" class="reference"><a href="#cite_note-Novartis_Bio-1">[1]</a></sup> On September 5, 2017, he was named the successor of <a href="/https/en.m.wikipedia.org/wiki/Joseph_Jimenez" title="Joseph Jimenez">Joseph Jimenez</a> as <a href="/https/en.m.wikipedia.org/wiki/CEO" class="mw-redirect" title="CEO">CEO</a> of <a href="/https/en.m.wikipedia.org/wiki/Novartis" title="Novartis">Novartis</a>.<sup id="cite_ref-Bloomberg_Announcement_2-0" class="reference"><a href="#cite_note-Bloomberg_Announcement-2">[2]</a></sup></p>
<p>He is a member of the U.S. <a href="/https/en.m.wikipedia.org/wiki/National_Academy_of_Medicine" title="National Academy of Medicine">National Academy of Medicine</a>.</p>
<ol class="references">
<li id="cite_note-Novartis_Bio-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-Novartis_Bio_1-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.novartis.com/sites/www.novartis.com/files/cv-vasant-narasimhan-en.pdf">"Vasant (Vas) Narasimhan"</a> <span style="font-size:85%;">(PDF)</span>. Novartis<span class="reference-accessdate">. Retrieved <span class="nowrap">5 September</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fen.wikipedia.org%3AVasant+Narasimhan&rft.btitle=Vasant+%28Vas%29+Narasimhan&rft.genre=unknown&rft.pub=Novartis&rft_id=https%3A%2F%2Fbackend.710302.xyz%3A443%2Fhttps%2Fwww.novartis.com%2Fsites%2Fwww.novartis.com%2Ffiles%2Fcv-vasant-narasimhan-en.pdf&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;"> </span></span></span></li>
<li id="cite_note-Bloomberg_Announcement-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-Bloomberg_Announcement_2-0">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/articles/2017-09-04/novartis-names-narasimhan-ceo-after-jimenez-retires-next-year">"Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor"</a>. <i>Bloomberg.com</i>. Bloomberg Technology. 4 September 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">5 September</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fen.wikipedia.org%3AVasant+Narasimhan&rft.atitle=Novartis+CEO+Jimenez+to+Quit%2C+Giving+Reins+to+Harvard+Doctor&rft.date=2017-09-04&rft.genre=article&rft.jtitle=Bloomberg.com&rft_id=https%3A%2F%2Fbackend.710302.xyz%3A443%2Fhttps%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2017-09-04%2Fnovartis-names-narasimhan-ceo-after-jimenez-retires-next-year&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;"> </span></span></span></li>
</ol>
<!--
NewPP limit report
Parsed by mw1264
Cached time: 20170905133345
Cache expiry: 1900800
Dynamic content: false
CPU time usage: 0.032 seconds
Real time usage: 0.034 seconds
Preprocessor visited node count: 62/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 3034/2097152 bytes
Template argument size: 0/2097152 bytes
Highest expansion depth: 2/40
Expensive parser function count: 0/500
Lua time usage: 0.015/10.000 seconds
Lua memory usage: 1.53 MB/50 MB
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00% 27.389 1 -total
86.13% 23.591 1 Template:Cite_web
13.60% 3.726 1 Template:Cite_news
-->
</div>' |
Whether or not the change was made through a Tor exit node (tor_exit_node) | 0 |
Unix timestamp of change (timestamp) | 1504618425 |
